A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2686-2693

  Wilgenhof, S ^a,b   Van Nuffel, A M T ^b   Benteyn, D ^b   Corthals, J ^b   Aerts, C ^b   Heirman, C ^b   Van Riet, I ^a   Bonehill, A ^b   Thielemans, K ^a,b   Neyns, B ^a,b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Dendritic cells; Immunotherapy; Melanoma; Trimixdc MEL

Indexed keywords

CYTOKINE; MESSENGER RNA;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL THERAPY; CELL VIABILITY; CLINICAL ARTICLE; DENDRITIC CELL; ELECTROPORATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; LYMPHOCYTIC INFILTRATION; MALE; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE;

DENDRITIC CELLS; IMMUNOTHERAPY; MELANOMA; TRIMIXDC-MEL;

ADULT; AGED; ANTIGENS, CD70; ANTIGENS, NEOPLASM; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; CELL- AND TISSUE-BASED THERAPY; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; ELECTROPORATION; FEMALE; HUMANS; IMMUNOTHERAPY; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 3; MALE; MELANOMA; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; SKIN NEOPLASMS; TOLL-LIKE RECEPTOR 4;

EID: 84884721824     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt245     Document Type: Article

References (21)

1. Boon T, Coulie PG, Van den Eynde BJ et al. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24: 175-208.
2. Rosenberg S, Yang J, Restifo N. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
3. Kruit W, van Ojik H, Brichard V et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005; 117: 596-604.
4. Chi M, Dudek AZ. Vaccine therapy for metastatic melanoma: systematic review and meta-analysis of clinical trials. Melanoma Res 2011; 21: 165-174.
5. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12: 265-277.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
7. Boudreau JE, Bonehill A, Thielemans K et al. Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther 2011; 19: 841-853.
8. SlingluffCL, Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21: 4016-4026.
9. O'Neill DW, Adams S, Goldberg JD et al. Comparison of the immunogenicity of Montanide ISA 51 adjuvant and cytokine-matured dendritic cells in a randomized controlled clinical trial of melanoma vaccines. ASCO Meeting Abstr 2009; 27: 3002.
10. Lesterhuis WJ, Aarntzen EH, De Vries IJ et al. Dendritic cell vaccines in melanoma: from promise to proof? Crit Rev Oncol Hematol 2008; 66: 118-134.
11. Bonehill A, Tuyaerts S, Van Nuffel AM et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008; 16: 1170-1180.
12. Bonehill A, Van Nuffel AM, Corthals J et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009; 15: 3366-3375.
13. Van Nuffel AM, Benteyn D, Wilgenhof S et al. Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients. Mol Ther 2012; 20: 1063-1074.
14. Van Nuffel AM, Benteyn D, Wilgenhof S et al. Intravenous and intradermal TriMixdendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012; 61: 1033-1043.
15. Bonehill A, Heirman C, Tuyaerts S et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004; 172: 6649-6657.
16. Wilgenhof S, Van Nuffel AM, Corthals J et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011; 34: 448-456.
17. Fong L, Brockstedt D, Benike C et al. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol 2001; 166: 4254-4259.
18. Mullins DW, Sheasley SL, Ream RM et al. Route of immunization with peptidepulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003; 198: 1023-1034.
19. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
20. Benteyn D, Van Nuffel AM, Wilgenhof S et al. Characterization of CD8(+) T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013; 2013: 976383.
21. Van Nuffel AM, Tuyaerts S, Benteyn D et al. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 2012; 377: 23-36.